The issue at hand appears to have officially shifted away from the suspicion that Stewart had inside information when she sold her holdings of ImClone Systems (nasdaq: IMCL - news - people ) oneday before the biotech company disclosed bad news about a drug, probably because there isn't enough evidence to suggest that she did so.